Galunisertib, a TGF-β receptor 1 inhibitor as a second-line therapy for HCC has been investigated, and the study reported that patients with low AFP levels had longer OS than those with high AFP (16.8 versus 7.3 months) [73] (Fig. 4E). Here, AFP is linked to hepatocellular carcinoma.